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Abstract We previously identi¢ed the Fas-associated factor
FAF1 as an in vitro substrate of protein kinase CK2 and deter-
mined Ser289 and Ser291 as phosphorylation sites. Here we
demonstrate that these two serine residues are the only sites
phosphorylated by CK2 in vitro, and that at least one site is
phosphorylated in vivo. Furthermore, we analyzed putative phys-
iological functions of FAF1 phosphorylation. The ability of
FAF1 to potentiate Fas-induced apoptosis is not in£uenced by
the FAF1 phosphorylation status; however, the nuclear import
of a phosphorylation-de¢cient FAF1 mutant was delayed in
comparison to wild-type FAF1.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
FAF1 was identi¢ed as a Fas-associated factor. Its function
has been described as potentiating Fas-induced apoptosis in a
mouse ¢broblast cell line (L cells) and in a human T-cell
tumor line (Jurkat) [1]. However, Ryu et al. [2] reported
that upon overexpression in BOSC23 cells it can initiate apo-
ptosis in the absence of an extrinsic death signal. FAF1 is
widely expressed in di¡erent adult and embryonic tissues
and in tumor cell lines [3,4] ; it localizes to the cytoplasm
and to the nucleus [3,5] ; it contains domains also present in
proteins of the ubiquitination pathway and a chromatin as-
sembly factor-like domain [4,6,7]. FAF1 seems to function as
a membrane-associated factor and as a nuclear factor. Roles
in apoptosis, in ubiquitin-related processes, during embryonic
di¡erentiation and in tumorigenesis have been suggested.
The mechanisms by which FAF1 exerts its di¡erent func-
tions are not known. Proteolytic processes might be of impor-
tance. A putative 40 kDa degradation product of FAF1 has
been found in various human cell lines [4]. We have found
after expression of recombinant FAF1 in Escherichia coli,
spontaneously occurring 40 kDa degradation products com-
prising amino acids 1^313 and 1^315 [8]. Interestingly, an
amino-terminal fragment of quail FAF1, FqFAFM1G467
caused apoptosis in COS cells [3]. The signi¢cance of the 40
kDa degradation product and its function remain to be inves-
tigated. Another regulatory mechanism might be through
posttranslational modi¢cations. We have previously identi¢ed
FAF1 as an interacting partner of the regulatory L-subunit of
the pleiotropic protein kinase CK2 [9] and as an in vitro
substrate of CK2 [8]. We have determined two serine residues,
namely serines 289 and 291, as in vitro phosphoacceptor sites.
Here, we investigated whether the two identi¢ed serine resi-
dues were the only possible sites being phosphorylated by
CK2 and whether these sites were phosphorylated in vivo.
In order to ¢nd a physiological function for the CK2-medi-
ated FAF1 phosphorylation, we analyzed the ability of FAF1
to potentiate Fas-induced apoptosis by using a phosphoryla-
tion-de¢cient FAF1 mutant. Since the phosphorylation sites
Ser289 and Ser291 are located within the nuclear localization
signal, we also investigated the subcellular localization of
wild-type and mutant FAF1.
2. Materials and methods
2.1. Generation of FAF1 constructs
The coding region of human FAF1 was cloned into the vectors
pQE30 (Qiagen), pEGFP N1 (Clontech) and pcDNA3.1/Myc-His(+)
C (Invitrogen). Mutant FAF1 constructs FAF1A289, FAF1A291 and
FAF1A289;291 with serines at positions 289 and/or 291 exchanged for
alanine were obtained using the QuickChange site-directed mutagen-
esis kit (Stratagene) according to the manufacturer’s instructions.
2.2. In vitro phosphorylation assay
Wild-type and mutant FAF1 constructs in the vector pQE30 were
used for bacterial expression in the bacterial strain M15[pREP4]. Pro-
teins were partially puri¢ed by a nickel nitriloacetic acid metal a⁄nity
chromatography and used for in vitro phosphorylation using recombi-
nant CK2 holoenzyme as described previously [8].
2.3. Preparation of FAF1 for matrix-assisted laser desorption/
ionization-mass spectrometry (MALDI-MS)
COS-1 cells were transfected with the wild-type FAF1 construct in
pcDNA3.1/Myc-His(+) C using the FuGENE1 6 transfection reagent
(Roche). 48 h after transfection cells were mechanically harvested and
suspended in 25 mM Tris/HCl, pH 8.5, 1 mM dithiothreitol (DTT),
100 mM NaCl containing 1U Protease inhibitor cocktail (Roche). A
lysate was prepared by sonication and cleared by centrifugation for 20
min at 4‡C and 12 000 rpm (Heraeus Megafuge 1.0). The supernatant
of a lysate from cells grown on a 10 cm plate was immunoprecipitated
using 2 Wg of anti-c-Myc antibody (sc-40, Santa Cruz, CA, USA).
Altogether protein lysates from eight 10 cm plates, each transfected
with 10 Wg pcDNA3.1/Myc-FAF1 plasmid DNA were immunopreci-
pitated. After separation on a sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE), the protein band containing FAF1
was in-gel digested with trypsin, and subdigested with chymotrypsin
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as previously described [8,10]. 0.1 M acetic acid was added and the
supernatant used for further IMAC (immobilized metal ion a⁄nity
chromatography) and subsequent MALDI-MS analyses.
2.4. IMAC and MALDI-MS analyses
IMAC was used to enrich phosphopeptides [11]. The Ni-NTA-silica
used for the IMAC column was charged with Fe3þ ions prior to use.
A 2 cm long column was prepared in a 10 Wl GELoader Tip (Eppen-
dorf), washed twice with 20 Wl 0.1 M acetic acid and loaded with the
sample, followed by two washing steps with 20 Wl 0.1 M acetic acid.
Peptides were eluted with either 1 Wl DHB matrix (H2O/100% aceto-
nitrile 1:1) directly on MALDI-MS target and subjected to MALDI-
MS analysis, or with 1 Wl ammonium solution, pH 10.5, into 0.5 Wl
50 mM NH4HCO3 placed on target and dephosphorylated before
MALDI-MS analysis. Dephosphorylation was done with 1 Wl alkaline
phosphatase (0.2 U/Wl, 50 mM NH4HCO3, pHv 7.8, Roche) on-tar-
get for 30 min at 37‡C in a wet chamber. The dephosphorylated
sample was mixed with 0.5 Wl DHB matrix and allowed to dry before
MALDI-MS analysis. Peptides were analyzed in a Bruker REFLEX
MALDI time-of-£ight mass spectrometer (Bruker-Daltonics) in pos-
itive re£ector mode and positive ion linear mode. The ion acceleration
voltage was set to 20 kV.
2.5. Transfection and Fas-induced apoptosis
Jurkat cells were transiently transfected with the wild-type or mu-
tant FAF1 constructs in pEGFP. 30 h after transfection cells were
incubated with 500 ng/ml of a monoclonal anti-human Fas antibody
(SM1/1, Chemicon) for 30 min at 4‡C and rinsed with prewarmed
medium. Fas-mediated apoptosis was induced by addition of 5 Wg/
ml secondary crosslinking antibody (alkaline phosphatase-conjugated
goat anti-mouse, Jackson Immunoresearch Laboratories). 16 h after
crosslinking the cells were stained with either trypan blue (Gibco
BRL) or with Hoechst 33342 (Sigma).
2.6. Subcellular localization
COS-1 cells grown on coverslips were transiently transfected with
wild-type or mutant FAF1 constructs in the vector pEGFP N1. 24 or
48 h after transfection cells were harvested. Before direct £uorescence
microscopy cells were incubated 20 min in the dark at room temper-
ature with Hoechst 33342 at a ¢nal concentration of 1 ng/ml. 100 cells
for each time point and transfection were analyzed by visual inspec-
tion.
3. Results and discussion
3.1. Ser289 and 291 are the only sites in the FAF1 protein
phosphorylated in vitro by CK2
We have previously identi¢ed the residues Ser289 and
Ser291 of the human FAF1 as in vitro CK2 phosphorylation
sites [8]. To determine if there are other CK2 phosphorylation
sites besides serines 289 and 291 within the FAF1 protein we
used recombinant FAF1 mutants with either one or both
serines exchanged for alanine for in vitro phosphorylation
using recombinant CK2 holoenzyme. The phosphorylated
proteins were resolved by SDS^PAGE, stained with Coomas-
sie blue (Fig. 1A) and visualized by autoradiography (Fig.
1B). The amount of incorporated phosphate per mole FAF1
was calculated based on quanti¢cation of the radioactive
bands (Fig. 1C). Wild-type FAF1 was phosphorylated to a
greater extent than the single FAF1 mutants. Incorporation
of phosphate was up to 1.3 mol/mol for wild-type FAF1 in-
dicating phosphorylation of more than one site, whereas mu-
tation of one of the two serines decreased the amount of
incorporated phosphate to approximately half, suggesting
that both serines are phosphorylated by recombinant CK2.
No phosphorylation was observed in the FAF1A289;291 double
mutant. This demonstrates that phosphorylation of FAF1 by
recombinant CK2 occurs at only these two previously identi-
¢ed residues, serine 289 and serine 291.
3.2. Identi¢cation of the in vivo phosphorylation site in human
FAF1
Next we wanted to know whether FAF1 is also phosphor-
ylated in vivo. We transfected COS-1 cells with a wild-type
human FAF1 expression construct, and immunoprecipitated
FAF1 from protein extracts, followed by separation on a
SDS^PAGE and in-gel digestion of FAF1 with trypsin. A
small fraction of the supernatant containing the tryptic pep-
tides was analyzed by MALDI-MS and thereby the identity of
FAF1 was con¢rmed (data not shown). Peptides were then
subdigested with chymotrypsin and phosphopeptides were en-
riched by an IMAC column. Analysis by MALDI-MS was
carried out before (Fig. 2A) and after dephosphorylation
(Fig. 2B).
The analysis of the phosphopeptide revealed phosphoryla-
tion of one peptide. The peptides at m/z 3974.5 and m/z 3990.2
correspond to the amino acid residues E276^F310, both con-
taining one phosphorylated serine. The latter peptide contains
an oxidized methionine and has therefore a correspondingly
higher molecular mass. A third peak, barely above back-
ground at m/z 3893.8 corresponds to the dephosphorylated
peptide (Fig. 2A). After dephosphorylation MALDI-MS anal-
ysis displayed two peptides at m/z 3894.5 and m/z 3910.9
corresponding to the amino acid residues E276^F310, with
one oxidized methionine in the latter (Fig. 2B). The mass
di¡erence before and after dephosphorylation is 80 Da, which
corresponds to a single phosphate group. This shows that one
residue in the peptide E276^F310 is phosphorylated in vivo.
The same phosphopeptide E276^F310 had been identi¢ed
after in vitro phosphorylation of FAF1 by CK2 [8].
The sequence of the chymotryptic peptide E276^F310 is
shown in Fig. 2C. It contains two threonine and three serine
residues, two of which are located in a bona ¢de CK2 con-
sensus sequence which requires an acidic residue at position
+3 [12], i.e. serines 289 and 291. This fact together with our




Fig. 1. In vitro phosphorylation of FAF1 constructs by recombinant
CK2 holoenzyme. A: Coomassie blue staining of recombinant wild-
type (wt) FAF1 constructs and constructs with amino acid ex-
changes at positions 289 and/or 291 after an in vitro phosphoryla-
tion reaction and SDS^PAGE. B: Corresponding autoradiography
displaying the radioactively labeled FAF1 protein. C: Quanti¢cation
of the radioactively labeled phosphate incorporated into the FAF1
protein.
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mutant in vitro implies that S289 and/or 291 are also phos-
phorylated in vivo. However, it could not be discerned which
of the two serines was phosphorylated. Since the two serines
are located so close together one might speculate that they
could easily substitute one another and are phosphorylated
equally well, as it has been shown in vitro.
3.3. CK2-mediated FAF1 phosphorylation does not a¡ect
potentiation of Fas-induced apoptosis
The only so far described physiological property of FAF1 is
to be a positive regulator of apoptosis [1,2]. Chu et al. dem-
onstrated that FAF1 potentiates Fas-induced apoptosis. To
examine whether phosphorylation of FAF1 by CK2 could
a¡ect this property, a transient apoptosis assay was per-
formed. Wild-type FAF1 and FAF1A289;291 were transiently
overexpressed in Jurkat cells. This cell line was chosen, since
it is responsive to Fas-induced apoptosis. Apoptosis was in-
duced by treatment with an anti-Fas antibody followed by
crosslinking with a secondary antibody. Dead and apoptotic
cells were visualized by trypan blue staining (Fig. 3A) and
Hoechst staining (Fig. 3B), respectively.
The wild-type FAF1 construct led to more dead and more
apoptotic cells upon treatment with the anti-Fas antibody
than it was observed in mock-transfected cells (Fig. 3). 24%
of control cells were apoptotic when treated with the anti-Fas
antibody, whereas this percentage increased to approximately
60% after transfection with the wild-type FAF1 construct.
Fas-induced apoptosis was neither increased nor decreased
by the phosphorylation-de¢cient FAF1 mutant FAF1A289;291
in comparison to wild-type FAF1, indicating that phosphor-
ylation of FAF1 by CK2 does not a¡ect potentiation of Fas-
induced apoptosis. However, a role for CK2 during apoptosis
has recently emerged [13] and for a number of proteins CK2-
mediated phosphorylation has an anti-apoptotic function, e.g.
phosphorylation of HS1 [14], Max [15], Bid [16] and connexin
45.6 [17] by CK2 prevents their cleavage by caspases and
ARC when phosphorylated by CK2 is targeted to mitochon-
dria where it inhibits caspase 8 [18].
It should be noted that transfection of FAF1 alone without
inducing Fas-mediated apoptosis did not cause apoptosis in
Jurkat cells (Fig. 3). Also overexpression of the phosphoryla-
tion-de¢cient FAF1A289;291 mutant alone was not su⁄cient to
induce apoptosis (data not shown). Interestingly, in BOSC23
cells mere overexpression of FAF1 was su⁄cient to initiate
apoptosis, and beside the UB2 domain of FAF1 also the
nuclear localization sequence which contains the CK2 phos-
phorylation sites was required [2]. Yet, neither in Jurkat cells,
as shown here, nor in L cells [1] or NIH3T3 ¢broblasts and
COS-7 cells [3], enhanced FAF1 expression led to apoptosis.
3.4. CK2-mediated phosphorylation of FAF1 in£uences its
nuclear localization
The FAF1 phosphorylation sites serine 289 and 291 are
located in a domain covering the residues 275^312 of the
human sequence. This domain has been shown to be respon-
sible for nuclear localization [3]. Therefore we analyzed the
e¡ects of CK2-mediated phosphorylation on the cellular local-
Fig. 2. Identi¢cation of the in vivo phosphorylation site in FAF1.
Tryptic/chymotryptic FAF1 phosphopeptides were isolated using
nanoscale FE(III) IMAC and analyzed by MALDI-MS. A: A single
peptide was detected carrying one phosphate group (m/z 3974.5).
B: After treatment with alkaline phosphatase, the mass of the major
peptide decreased by 80 Da (m/z 3894.5). C: The sequence of the
chymotryptic peptide 276^310 from FAF1. Serines and threonines
are indicated by arrowheads, the two possible CK2 phosphorylation
sites are indicated by attached phosphate groups (P).
Fig. 3. In£uence of wild-type FAF1 and a phosphorylation-de¢cient
FAF1 mutant on Fas-induced apoptosis. Jurkat cells were trans-
fected with the empty vector (pEGFP), wild-type (wt) FAF1 or mu-
tant FAF1A289;291 constructs in the vector pEGFP followed by anti-
Fas antibody crosslinking as described in Section 2. A: Dead cells
were counted after staining with trypan blue. B: Cells were stained
with Hoechst and apoptotic cells were counted among transfected
cells using £uorescence microscopy.
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ization of FAF1. COS-1 cells were transiently transfected with
wild-type FAF1 or FAF1A289;291 constructs, tagged with
EGFP. 24 and 48 h after transfection, localization of FAF1
was analyzed directly by immuno£uorescence microscopy
(Fig. 4).
Transfection with wild-type FAF1 resulted in a predomi-
nantly nuclear localization. FAF1 was distributed homoge-
neously over the nuclei but excluded from the nucleoli 24
and 48 h after transfection (Fig. 4). By contrast the FAF1
mutant FAF1A289;291, which cannot be phosphorylated,
showed a di¡erent localization 24 h after transfection. Two
cell populations were detected. In approximately two third of
the cells (population 1) the FAF1 mutant showed the same
cellular localization as the wild-type FAF1, whereas in about
one third of the cells (population 2) a predominantly cytoplas-
mic, perinuclear staining was observed. 48 h after transfection
with FAF1A289;291 all cells had the protein predominantly in
the nucleus, but it was excluded from the nucleoli. The results
were the same for proteins tagged with a myc epitope instead
of EGFP and analyzed by immunostaining (not shown). By
using anti-FAF1 antibodies the described results were also
con¢rmed (not shown).
Although it is known that the cell cycle and/or the state of
con£uency can in£uence the phosphorylation state of proteins
and their cellular localization, wild-type FAF1 was, in all cells
analyzed, predominantly found in the nucleus. Since CK2 is
constitutively active during all stages of the cell cycle [19], one
might speculate that FAF1 is phosphorylated all the time.
30% of the cells transfected with a phosphorylation-de¢cient
FAF1 mutant did not show the predominant nuclear local-
ization. Therefore we assume that CK2-mediated FAF1 phos-
phorylation in£uences the nuclear localization of FAF1. It
seems that abrogation of phosphorylation does not com-
pletely inhibit the nuclear transport, but slows down the im-
port of FAF1 into the nucleus.
The predominant nuclear localization of FAF1 and exclu-
sion from the nucleoli is in agreement with results from Froh-
lich et al. [3]. However, it implies that the major function of
FAF1 might not be in the cytoplasm as an interacting partner
of Fas. The accumulation of FAF1 in the nucleus is obviously
regulated by several means, among them phosphorylation by
CK2. But phosphorylation is not an exclusive signal as it is
the case for many other proteins. E.g. phosphorylation of the
large T-antigen by CK2 increases the rate of nuclear import
from 10 h for a phosphorylation-de¢cient T-antigen mutant to
15^20 min when the T-antigen is phosphorylated by CK2 [20].
Also the nuclear import of IFI 16 and of nucleoplasmin are
regulated by CK2 phosphorylation [21,22]. Current models
for mechanisms of regulation of nuclear transport also involve
ubiquitination [23], which was shown to be necessary for
transport of NF-UB across the nuclear membrane. Further
studies are necessary to reveal whether the ubiquitin binding
domain and the ubiquitin-like domains of FAF1 do have a
contribution in this respect. In mouse models for cardiac hy-
pertrophy, susceptible for apoptosis but not showing apopto-
sis, high levels of FAF1 were detected, supporting the notion
of FAF1 not only being con¢ned to Fas association but also
being involved in other yet unknown functions [24]. Hence,
special importance will be to elucidate the nuclear function of
FAF1.
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Fig. 4. Subcellular localization of wild-type FAF1 and a phosphorylation-de¢cient FAF mutant. COS-1 cells were transfected with wild-type
(wt) FAF1 or mutant FAF1A289;291 constructs in the vector pEGFP and analyzed by £uorescence microscopy for EGFP and parallel Hoechst
staining 24 and 48 h (h) after transfection. The pictures shown for FAF1A289;291, population 1 and population 2, 24 h after transfection repre-
sent 70 and 30% of the cells, respectively.
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